Universidad Nacional de Hurlingham
metadata only
Vismodegib in PAMAM-dendrimers for potential theragnosis in skin cancer
Vismodegib (VDG) is an antineoplastic, a first-in-class Hedgehog signaling pathway inhibitor, indicated to treat locally advanced or metastatic basal cell carcinoma. Treatment with this drug was approved in 2012 by the US-FDA for oral administration (dose of 150 mg per day) in patients with a refusa
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- CSD190401: A Study to Assess Elements of Abuse Liability for Nicotine-containing Pouch Tobacco Products#811707
- Lercanidipine hydrochloride 10mg#380078
- LERCANIDIPINUM 10 MG/ COMP#135187
- DOSAGGIO ENDOTOSSINE#367364
- Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer#917237
Record · ID 1023306
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive